Results 11 to 20 of about 94 (55)

Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. [PDF]

Proc Natl Acad Sci U S A, 2020
Liu X, Wang Y, Gutierrez JS, Damsker JM, Nagaraju K, Hoffman EP, Ortlund EA.   +6 more
europepmc   +1 more source

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.

JAMA Netw Open, 2022
Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ, NorthStar UK Network and CINRG DNHS Investigators.   +27 more
europepmc   +1 more source

Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. [PDF]

Hum Mol Genet, 2020
Dang UJ, Ziemba M, Clemens PR, Hathout Y, Conklin LS, CINRG Vamorolone 002/003 Investigators, Hoffman EP.   +6 more
europepmc   +1 more source

Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset. [PDF]

Inflamm Res, 2019
Damsker JM, Cornish MR, Kanneboyina P, Kanneboyina I, Yu Q, Lipson R, Phadke A, Knoblach SM, Panchapakesan K, Morales M, Fiorillo AA, Partridge T, Nagaraju K.   +12 more
europepmc   +1 more source

(3β,16α)-3,16-Dihydroxypregn-5-en-20-one from the Twigs of Euonymus alatus (Thunb.) Sieb. Exerts Anti-Inflammatory Effects in LPS-Stimulated RAW-264.7 Macrophages. [PDF]

Molecules, 2019
Lee S, Lee D, Baek SC, Jo MS, Kang KS, Kim KH.   +5 more
europepmc   +1 more source

Reply: To PMID 25174863. [PDF]

J Allergy Clin Immunol, 2015
Dixon AE, Castro M, Cohen RI, Gerald LB, Holbrook JT, Irvin CG, Mohapatra S, Peters SP, Rayapudi S, Sugar EA, Wise RA, American Lung Association–Asthma Clinical Research Centers.   +11 more
europepmc   +1 more source

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy. [PDF]

J Neurol
Lochmüller H, Gonorazky H, Nigro E, Mah JK, Alemán A, Yaworski A, Oskoui M, Sbrocchi AM, Selby K, de Vera A, McAdam L, Gresko E, Linden A, Dutreix C, Hoffman EP.   +14 more
europepmc   +1 more source

Vamorolone: a novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects. [PDF]

Rheumatology (Oxford)
Crastin A, Shanker A, Sagmeister MS, Taylor A, Lavery GG, Raza K, Hardy RS.   +6 more
europepmc   +1 more source

Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy. [PDF]

Neurol Sci
Ibrahim MS, Abdelwahab OA, Elawfi B, Ali FY, Amro S, Mohammed SF, Shaheen N, Negida A, Arndt M, Hijazi MM, Schaefer J, Siepmann T.   +11 more
europepmc   +1 more source

Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. [PDF]

J Clin Pharmacol, 2019
Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, Jusko WJ.   +7 more
europepmc   +1 more source